Tumor Volume Decrease at 8 Weeks Is Associated with Longer Survival in EGFR-Mutant Advanced Non–Small-Cell Lung Cancer Patients Treated with EGFR TKI
Mizuki Nishino, Suzanne Eleanor Dahlberg, Stephanie Cardarella et al. · Journal of Thoracic Oncology · 2013
Cited by 53 works. doi:10.1097/jto.0b013e318294c909
Authors
- Mizuki Nishino
- Suzanne Eleanor Dahlberg
- Stephanie Cardarella
- David Michael Jackman
- Michael S. Rabin
- Hiroto Hatabu
- Pasi Antero Janne
- Bruce Evan Johnson
References
- New Guidelines to Evaluate the Response to Treatment in Solid Tumors
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
- 1969 Cancer Facts and Figures
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- Cancer statistics, 2012
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib